© 2011. ias–usa johnson va et al. top antivir med. 2011;19(4):156-164. updates, user notes, and...

© 2011. IAS–USA© 2011. IAS–USA

Johnson VA et al. Johnson VA et al. Top Antivir MedTop Antivir Med. 2011;19(4):156-164. . 2011;19(4):156-164. Updates, user notes, and references available at www.iasusa.org. Updates, user notes, and references available at www.iasusa.org.

Mutations in the Reverse Transcriptase Gene Associated with Resistance to Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)Mutations in the Reverse Transcriptase Gene Associated with Resistance to Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)

Multi-nRTI Resistance: 69 Insertion Complex (affects all nRTIs currently approved by the US FDA)

Multi-nRTI Resistance: 151 Complex (affects all nRTIs currently approved by the US FDA except tenofovir)

Multi-nRTI Resistance: Thymidine Analogue-Associated Mutations (TAMs; affect all nRTIs currently approved by the US FDA)



Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nucleoside and Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs) Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs) (cont)

Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nucleoside and Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs) Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs) (cont)

Abacavir

Didanosine

Emtricitabine

Lamivudine

Stavudine

Tenofovir

Zidovudine



Mutations in the Reverse Transcriptase Gene Associated with Resistance to Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)Mutations in the Reverse Transcriptase Gene Associated with Resistance to Mutations in the Reverse Transcriptase Gene Associated with Resistance to Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)

Efavirenz

Etravirine

Nevirapine

Rilpivirine



Mutations in the Protease Gene Associated with Resistance to Protease InhibitorsMutations in the Protease Gene Associated with Resistance to Protease Inhibitors

Atazanavir +/-ritonavir

Darunavir/ritonavir

Fosamprenavir/ritonavir

Indinavir/ritonavir

Lopinavir/ritonavir



Mutations in the Protease Gene Associated with Resistance to Protease Inhibitors (cont)

Mutations in the Protease Gene Associated with Resistance to Protease Inhibitors (cont)

Nelfinavir

Tipranavir/ritonavir

Saquinavir/ritonavir



Mutations in the Envelope Gene Associated With Resistance to Mutations in the Envelope Gene Associated With Resistance to Entry InhibitorsEntry InhibitorsMutations in the Envelope Gene Associated With Resistance to Mutations in the Envelope Gene Associated With Resistance to Entry InhibitorsEntry Inhibitors

Maraviroc

Enfuvirtide

User Notes available at www.iasusa.org



Mutations in the Integrase Gene Associated With Resistance to Mutations in the Integrase Gene Associated With Resistance to Integrase InhibitorsIntegrase InhibitorsMutations in the Integrase Gene Associated With Resistance to Mutations in the Integrase Gene Associated With Resistance to Integrase InhibitorsIntegrase Inhibitors

Raltegravir



IASIASUSA* Drug Resistance Mutations GroupUSA* Drug Resistance Mutations Group

*IAS–USA is a not-for-profit, HIV clinical specialist-education organization. It is entirely different from and not affiliated with the International AIDS Society (Stockholm, Sweden).

2011 Update of the Drug Resistance Mutations in HIV-1Victoria A. Johnson, MD, Vincent Calvez, MD, PhD, Huldrych F. Günthard, MD, Roger Paredes, MD, PhD, Deenan Pillay, MD, PhD, Robert Shafer, MD, Annemarie M. Wensing, MD, PhD, and Douglas D. Richman, MD

Top Antivir Med. 19(4):156-164. Updates available at www.iasusa.org.

© 2011. ias–usa johnson va et al. top antivir med. 2011;19(4):156-164. updates, user notes, and...

Documents